Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease
- PMID: 23222419
- PMCID: PMC3616764
- DOI: 10.1093/ndt/gfs417
Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease
Abstract
Background: Hyperuricemia has been implicated in the development and progression of chronic kidney disease, both in animal experiments and in clinical studies. As a potentially modifiable risk factor, we examined whether serum uric acid levels correlate with early hypertension, kidney volume and progression to end-stage renal disease (ESRD) in autosomal-dominant polycystic kidney disease (ADPKD).
Methods: Retrospective analysis of a prospective observational study of the natural history of ADPKD, conducted at the University of Colorado between 1985 and 2005. Included are 680 ADPKD adults who provided data on blood pressure, renal volume, renal function, uric acid, age at the onset of ESRD or last known age without ESRD. Serum uric acid levels were examined as a continuous variable and as gender-specific quartiles. The main outcome of interest was age at the onset of ESRD; secondary outcomes were hypertension onset before age 30 years and total kidney volume (TKV) at the study visit.
Results: Subjects with early-onset hypertension had higher age-adjusted serum uric acid levels than those with no or late-onset hypertension despite similar creatinine clearance. After adjusting for age, gender and creatinine clearance, there was a 5.8% increase in TKV and 4.1% increase in TKV/body surface area for every 1 mg/dL increase in uric acid (P = 0.007). The multivariate-adjusted Cox regression demonstrated a greater hazard ratio for ESRD for subjects in the 4th and 3rd quartiles of uric acid compared with the 1st [4.8 (2.6-8.9; P < 0.001) and 2.9 (1.6-5.3; P < 0.001)].
Conclusions: Higher serum uric acid levels are associated with earlier onset of hypertension, larger kidney volume and increased hazard for ESRD in ADPKD independent of gender, body mass index and renal function at the study visit. Randomized interventional studies will be necessary to examine whether treating hyperuricemia has a protective role in ADPKD.
Figures
Similar articles
-
Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.BMC Nephrol. 2019 Feb 25;20(1):66. doi: 10.1186/s12882-019-1249-6. BMC Nephrol. 2019. PMID: 30803434 Free PMC article. Clinical Trial.
-
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.PLoS Med. 2019 Apr 5;16(4):e1002777. doi: 10.1371/journal.pmed.1002777. eCollection 2019 Apr. PLoS Med. 2019. PMID: 30951521 Free PMC article. Clinical Trial.
-
Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).Clin Exp Nephrol. 2021 Sep;25(9):970-980. doi: 10.1007/s10157-021-02068-x. Epub 2021 Apr 29. Clin Exp Nephrol. 2021. PMID: 33928479
-
[Renal manifestation of Autosomal Dominant Polycystic Kidney Disease].G Ital Nefrol. 2018 Mar;35(2):2018-vol2. G Ital Nefrol. 2018. PMID: 29582957 Review. Italian.
-
Clinical and laboratory markers of autosomal dominant polycystic kidney disease (ADPKD) progression: an overview.Minerva Med. 2015 Feb;106(1):53-64. Epub 2014 Oct 10. Minerva Med. 2015. PMID: 25300895 Review.
Cited by
-
The importance of total kidney volume in evaluating progression of polycystic kidney disease.Nat Rev Nephrol. 2016 Nov;12(11):667-677. doi: 10.1038/nrneph.2016.135. Epub 2016 Oct 3. Nat Rev Nephrol. 2016. PMID: 27694979 Free PMC article. Review.
-
Uric acid, hypertension, and cardiovascular and renal complications.Curr Hypertens Rep. 2013 Dec;15(6):531-7. doi: 10.1007/s11906-013-0391-y. Curr Hypertens Rep. 2013. PMID: 24072559 Review.
-
A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease.BMC Nephrol. 2015 Aug 15;16:140. doi: 10.1186/s12882-015-0114-5. BMC Nephrol. 2015. PMID: 26275819 Free PMC article.
-
Biomarkers of Kidney Disease Progression in ADPKD.Kidney Int Rep. 2024 Jul 14;9(10):2860-2882. doi: 10.1016/j.ekir.2024.07.012. eCollection 2024 Oct. Kidney Int Rep. 2024. PMID: 39435347 Free PMC article. Review.
-
Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus.Can J Kidney Health Dis. 2017 Mar 1;4:2054358117695784. doi: 10.1177/2054358117695784. eCollection 2017. Can J Kidney Health Dis. 2017. PMID: 28321325 Free PMC article.
References
-
- Iglesias CG, Torres VE, Offord KP, et al. Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935–1980. Am J Kidney Dis. 1983;2:630–639. - PubMed
-
- Ecder T, Fick-Brosnahan GM, Schrier RW. Polycystic kidney disease. In: Schrier RW, editor. Diseases of the Kidney and Urinary Tract. 8th edn. Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 502–539.
-
- Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol. 1997;8:1560–1567. - PubMed
-
- Wang D, Iversen J, Wilcox CS, et al. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal dominant polycystic kidney disease. Kidney Int. 2003;64:1381–1388. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials